| Year |
Citation |
Score |
| 2023 |
Prahallad A, Weiss A, Voshol H, Kerr G, Sprouffske K, Yuan T, Ruddy D, Meistertzheim M, Kazic-Legueux M, Kottarathil T, Piquet M, Cao Y, Martinuzzi-Duboc L, Buhles A, Alder F, et al. CRISPR screening identifies mechanisms of resistance to KRASG12C and SHP2 inhibitor combinations in non-small cell lung cancer. Cancer Research. PMID 37934115 DOI: 10.1158/0008-5472.CAN-23-1127 |
0.332 |
|
| 2019 |
Sulahian R, Kwon JJ, Walsh KH, Pailler E, Bosse TL, Thaker M, Almanza D, Dempster JM, Pan J, Piccioni F, Dumont N, Gonzalez A, Rennhack J, Nabet B, Bachman JA, ... ... Yuan TL, et al. Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. Cell Reports. 29: 118-134.e8. PMID 31577942 DOI: 10.1016/J.Celrep.2019.08.090 |
0.44 |
|
| 2019 |
Lee CS, Lee LC, Yuan TL, Chakka S, Fellmann C, Lowe SW, Caplen NJ, McCormick F, Luo J. MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival. Proceedings of the National Academy of Sciences of the United States of America. PMID 30709910 DOI: 10.1073/Pnas.1817494116 |
0.6 |
|
| 2018 |
Yuan TL, Amzallag A, Bagni R, Yi M, Afghani S, Burgan W, Fer N, Strathern LA, Powell K, Smith B, Waters AM, Drubin D, Thomson T, Liao R, Greninger P, et al. Differential Effector Engagement by Oncogenic KRAS. Cell Reports. 22: 1889-1902. PMID 29444439 DOI: 10.1016/J.Celrep.2018.01.051 |
0.553 |
|
| 2015 |
Amzallag A, Yuan TL, Bagni R, Yi M, Stephens R, Ramawamy S, McCormick F, Benes CH. Abstract LB-247: Querying the RAS genomic network with siRNAs and and flow cytometry: Automatic, multidimensional phenotyping of 135 cancer cell lines by Gaussian mixture fitting and expectation maximization Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-247 |
0.358 |
|
| 2015 |
Yuan TL, Bagni R, Yi M, Amzallag A, Afghani S, Beam K, Burgan W, Fer N, Garvey L, Smith B, Waters A, Stephens R, Benes C, McCormick F. Abstract 4690: Next-generation screen for integrative subtyping and target discovery for KRAS-mutant cancer Cancer Research. 75: 4690-4690. DOI: 10.1158/1538-7445.Am2015-4690 |
0.499 |
|
| 2014 |
Yuan TL, Fellmann C, Lee CS, Ritchie CD, Thapar V, Lee LC, Hsu DJ, Grace D, Carver JO, Zuber J, Luo J, McCormick F, Lowe SW. Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discovery. 4: 1182-97. PMID 25100204 DOI: 10.1158/2159-8290.Cd-13-0900 |
0.518 |
|
| 2013 |
Yuan TL, McCormick F. Killing tumors by keeping ras and PI3' kinase apart. Cancer Cell. 24: 562-3. PMID 24229705 DOI: 10.1016/J.Ccr.2013.10.015 |
0.426 |
|
| 2013 |
Yuan TL, Lee C, Fellmann C, Ritchie C, Lee C, Merrifield C, Schluep T, Lowe SW, Luo J, McCormick F. Abstract LB-94: Nanoparticle-based RNAi therapy for the delivery of personalized siRNA payloads to KRAS-driven tumors. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-94 |
0.559 |
|
| 2011 |
Yuan TL, Wulf G, Burga L, Cantley LC. Cell-to-cell variability in PI3K protein level regulates PI3K-AKT pathway activity in cell populations. Current Biology : Cb. 21: 173-83. PMID 21256021 DOI: 10.1016/J.Cub.2010.12.047 |
0.496 |
|
| 2010 |
Yuan TL, Cantley LC. Introduction. Current Topics in Microbiology and Immunology. 346: 1-7. PMID 20582535 DOI: 10.1007/82_2010_55 |
0.436 |
|
| 2008 |
Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 27: 5497-510. PMID 18794884 DOI: 10.1038/Onc.2008.245 |
0.519 |
|
| 2008 |
Yuan TL, Choi HS, Matsui A, Benes C, Lifshits E, Luo J, Frangioni JV, Cantley LC. Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. 105: 9739-44. PMID 18621722 DOI: 10.1073/Pnas.0804123105 |
0.519 |
|
| Show low-probability matches. |